Unicycive Therapeutics, Inc. Common Stock (UNCY) is a publicly traded Healthcare sector company. As of May 21, 2026, UNCY trades at $7.82 with a market cap of $217.61M and a P/E ratio of -4.58. UNCY moved +0.13% today. Year to date, UNCY is +40.22%; over the trailing twelve months it is +29.00%. Its 52-week range spans $3.40 to $11.00. Analyst consensus is strong buy with an average price target of $45.43. Rallies surfaces UNCY's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Unicycive Secures June 29 PDUFA Date for Oxylanthanum Carbonate NDA, Prepares Launch: Unicycive ended Q1 with $57.1 million in cash and equivalents, funding operations into 2027, and posted a $12.8 million loss ($0.54 per share) due to warrant liability revaluation. The FDA accepted its oxylanthanum carbonate NDA resubmission with a June 29, 2026 PDUFA date as the company advances launch preparations.
| Metric | Value |
|---|---|
| Price | $7.82 |
| Market Cap | $217.61M |
| P/E Ratio | -4.58 |
| EPS | $-1.67 |
| Dividend Yield | 0.00% |
| 52-Week High | $11.00 |
| 52-Week Low | $3.40 |
| Volume | 6 |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $-26.55M |
| Gross Margin | 0.00% |
7 analysts cover UNCY: 0 strong buy, 7 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $45.43.